Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

Ontherag Jun. 4 at 10:25 PM

$PDSB 1.2M

1 · Reply

JohntyCT Jun. 4 at 10:17 PM

$PDSB this is a weird run, right? Frank is hated, trial paused, Yorkville looming. Guess it’s the perfect contrarian setup? Even my AI agents tell me to tread carefully.

1 · Reply

MikiTrader Jun. 4 at 7:59 PM

$PDSB Russell

0 · Reply

Lovethespace27 Jun. 4 at 7:53 PM

$PDSB PDSB will run out of cash in a matter of weeks. News flow is sparse—or virtually non-existent. The main clinical trial is stalled, yet we continue to climb amidst high volatility. It’s a scenario similar to the one just before the acquisition of F-star Therapeutics four years ago. An acquisition or partnership could happen as early as this June! Hold the line, OGs!

1 · Reply

dvice2 Jun. 4 at 1:17 PM

$PDSB we’re way overdue for some kind of catalyst.. itll hit at some point. just have to hope its a positive one 😆

1 · Reply

i81b4u Jun. 4 at 12:40 PM

$PDSB Facebook post.

0 · Reply

Ontherag Jun. 3 at 9:41 PM

$PDSB

0 · Reply

JohntyCT Jun. 3 at 5:54 PM

$PDSB I bought more today and I probably again own more of this than I should, particularly given Frank’s history of never exceeding expectations. I keep thinking that they will find someone to fund this Phase 3 trial. But then again maybe I am deluding myself!

1 · Reply

focafoca99 Jun. 2 at 7:46 PM

$PDSB recovered Nasdaq compliance by meeting the $1 minimum bid price requirement.

1 · Reply

i81b4u Jun. 2 at 7:42 PM

$PDSB Didn't this already happen?

1 · Reply

PDS Biotechnology Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 22 days ago

PDS Biotechnology Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 22 days ago

PDS Biotechnology Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 22 days ago

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

May 6, 2026, 8:00 AM EDT - 4 weeks ago

PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

PDS Biotechnology Registration statement: Registration filing

Apr 22, 2026, 7:00 AM EDT - 6 weeks ago

PDS Biotechnology Slides: Corporate presentation

2026-04-15T13:37:04.000Z - 7 weeks ago

PDS Biotechnology announces positive Phase 2 trial data for PDS01ADC

Apr 15, 2026, 8:45 AM EDT - 7 weeks ago

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

Mar 30, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Annual report: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 2 months ago

PDS Biotechnology Earnings release: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 2 months ago

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Mar 24, 2026, 4:05 PM EDT - 2 months ago

PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

Feb 20, 2026, 8:30 AM EST - 3 months ago

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Jan 28, 2026, 8:45 AM EST - 4 months ago

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Jan 22, 2026, 8:45 AM EST - 4 months ago

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

Jan 9, 2026, 8:45 AM EST - 5 months ago

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Dec 9, 2025, 8:00 AM EST - 6 months ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 6 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 8:00 AM EST - 7 months ago

PDS Biotechnology Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

PDS Biotechnology Quarterly report: Q3 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

PDS Biotechnology Earnings release: Q3 2025

Nov 13, 2025, 7:30 AM EST - 7 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 7 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 7 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 7 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 7 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 9 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 29, 2025, 8:00 AM EDT - 9 months ago

PDS Biotechnology Registration statement: Registration Filing

Aug 25, 2025, 8:30 AM EDT - 10 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 8:00 AM EDT - 10 months ago

PDS Biotechnology Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 10 months ago

PDS Biotechnology Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 10 months ago

PDS Biotechnology Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 17, 2025, 12:00 PM EDT - 1 year ago

PDS Biotechnology Transcript: Status Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Registration statement: Registration Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Transcript: Study Update

May 23, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Press release: Study Update

May 22, 2025, 5:26 PM EDT - 1 year ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

May 21, 2025, 5:20 PM EDT - 1 year ago

PDS Biotechnology Transcript: A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 1 year ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Proxy statement: Proxy Filing

Apr 23, 2025, 10:16 AM EDT - 1 year ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Annual report: Q4 2024

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 2:30 PM EDT - 1 year ago

PDS Biotechnology Transcript: Life Sciences Virtual Investor Conference

Mar 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 1 year ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Earnings release: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 9:30 AM EDT - 1 year ago

PDS Biotechnology Quarterly report: Q2 2024

Aug 13, 2024, 9:30 AM EDT - 1 year ago

PDS Biotechnology Earnings release: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Ontherag Jun. 4 at 10:25 PM

$PDSB 1.2M

1 · Reply

JohntyCT Jun. 4 at 10:17 PM

$PDSB this is a weird run, right? Frank is hated, trial paused, Yorkville looming. Guess it’s the perfect contrarian setup? Even my AI agents tell me to tread carefully.

1 · Reply

MikiTrader Jun. 4 at 7:59 PM

$PDSB Russell

0 · Reply

Lovethespace27 Jun. 4 at 7:53 PM

1 · Reply

dvice2 Jun. 4 at 1:17 PM

$PDSB we’re way overdue for some kind of catalyst.. itll hit at some point. just have to hope its a positive one 😆

1 · Reply

i81b4u Jun. 4 at 12:40 PM

$PDSB Facebook post.

0 · Reply

Ontherag Jun. 3 at 9:41 PM

$PDSB

0 · Reply

JohntyCT Jun. 3 at 5:54 PM

1 · Reply

focafoca99 Jun. 2 at 7:46 PM

$PDSB recovered Nasdaq compliance by meeting the $1 minimum bid price requirement.

1 · Reply

i81b4u Jun. 2 at 7:42 PM

$PDSB Didn't this already happen?

1 · Reply

Ontherag Jun. 2 at 5:38 PM

$PDSB https://www.biospace.com/drug-development/asco-modernas-mrna-based-melanoma-vaccine-shows-encouraging-5-year-survival

2 · Reply

Mr_Charlie Jun. 2 at 5:05 PM

$PDSB big noise going around with amivantamab from Jansen (J&J) and here we are without any news. We are losing momentum, losing opportunnities and losing hope of ever having a drug approved.

0 · Reply

Juliodough Jun. 2 at 3:07 AM

$PDSB …someone is asleep at the wheel so i’ll cover for em’ 1.4 million. not dead yet

1 · Reply

Ontherag Jun. 1 at 3:54 PM

$PDSB 850k

1 · Reply

Llamalamb2921 Jun. 1 at 2:09 PM

$PDSB BioNTech comes out with phase 2/3 interim data on Messenger RNA treatment for HPV16+ Head and Neck cancer in 2026 according to ChatGPT. This could be our next catalyst or our ultimate failure.

1 · Reply

JohntyCT May. 29 at 8:00 PM

$PDSB not a bad looking level 2 order just before close. Showing some good support.

0 · Reply

JohntyCT May. 29 at 3:49 PM

$PDSB we used to be so excited for ASCO, Frank…. 🤪

2 · Reply

Ontherag May. 28 at 8:43 PM

$PDSB

0 · Reply

Ontherag May. 28 at 8:04 PM

$PDSB 2M volume day lol

1 · Reply

EddieH2020 May. 28 at 6:13 PM

$PDSB I gave you all SLS while it was early just saying …

0 · Reply

i81b4u May. 28 at 2:42 PM

$PDSB what is this?

1 · Reply

ThatNurseDude May. 28 at 1:01 AM

$PDSB 3 year ago ph3 was supposed to start. redesign after redesign for the sake of saving money and time, yet here we are with a fucking stalled ph3 with no money and no time. What a fucking failure you are, Frank.

2 · Reply

Market Cap	60.28M
Revenue (ttm)	0.00
Net Income (ttm)	-34.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	2.73

Volume	1,175,100
Avg Vol	1,108,902
Day's Range	N/A - N/A
Shares Out	55.82M
Stochastic %K	76%
Beta	1.57
Analysts	Strong Sell
Price Target	$7.50